The power and pitfalls of omics part 2: epigenomics, transcriptomics and ME/CFS
Simon McGrath concludes his blog about the remarkable Prof George Davey Smith's smart ideas for understanding diseases, which may soon be applied to ME/CFS.
Discuss the article on the Forums.

Excerpts: Hemispherx presentation on Ampligen, XMRV, Nov 18, 2010

Discussion in 'Active Clinical Studies' started by JohnnyD, Nov 19, 2010.

  1. JohnnyD

    JohnnyD Senior Member

    Messages:
    189
    Likes:
    345
    This is a nicely detailed summary of an investor conference, with all the other Hemispherx programs (flu, cancer) excerpted out.

    http://www.facebook.com/note.php?note_id=469940716796&comments&ref=mf

    One additional thing that was said on Tuesday, the 16th, during a Quarterly conference call and that relates directly to the slide 12 bar graph in the link above -- is that Hemispherx thinks they have a therapeutic surrogate marker for XMRV->CFS. IOW, patients that test positive, respond best. WPI is culturing their 516 trial participants and they only have about 10-15% of the data they want. They figure they need 60-85% of the data to approach the FDA again. A peer reviewed CFS/QT interval paper should be published very soon.
     
  2. Rooney

    Rooney Senior Member

    Messages:
    103
    Likes:
    46
    SE USA
    From where will this extra data come? There are so very few current trial participants, if Hunter-Hopkins in Charlotte is any indication. Any ideas on this?

    Thanks Johnny D.
     
  3. JohnnyD

    JohnnyD Senior Member

    Messages:
    189
    Likes:
    345
    Hi Rooney,

    This is retrospective analysis of their completed AMP516 pivotal trial. The 516 trial ended well before the WPI discovered the XMRV/CFS association. With WPI's help, they are doing serology and culture on the 516 participants and then comparing that data to how well the ampligen arm did on the ETT (Exercise Tolerance Test).
     

See more popular forum discussions.

Share This Page